- Home
- CORT vs PRCT Comparison
CORT vs PRCT Comparison
Compare CORT & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CORT
- PRCT
- Stock Information
- Founded
- CORT 1998
- PRCT 2009
- Country
- CORT United States
- PRCT United States
- Employees
- CORT N/A
- PRCT N/A
- Industry
- CORT Biotechnology: Pharmaceutical Preparations
- PRCT Medical Specialities
- Sector
- CORT Health Care
- PRCT Health Care
- Exchange
- CORT Nasdaq
- PRCT Nasdaq
- Market Cap
- CORT 5.9B
- PRCT 5.3B
- IPO Year
- CORT N/A
- PRCT 2021
- Fundamental
- Price
- CORT $53.63
- PRCT $83.53
- Analyst Decision
- CORT Strong Buy
- PRCT Strong Buy
- Analyst Count
- CORT 4
- PRCT 7
- Target Price
- CORT $75.25
- PRCT $97.86
- AVG Volume (30 Days)
- CORT 824.2K
- PRCT 549.3K
- Earning Date
- CORT 02-13-2025
- PRCT 10-28-2024
- Dividend Yield
- CORT N/A
- PRCT N/A
- EPS Growth
- CORT 57.97
- PRCT N/A
- EPS
- CORT 1.26
- PRCT N/A
- Revenue
- CORT $628,555,000.00
- PRCT $199,843,000.00
- Revenue This Year
- CORT $46.29
- PRCT $67.07
- Revenue Next Year
- CORT $17.09
- PRCT $40.64
- P/E Ratio
- CORT $42.54
- PRCT N/A
- Revenue Growth
- CORT 39.67
- PRCT 71.71
- 52 Week Low
- CORT $20.84
- PRCT $39.48
- 52 Week High
- CORT $62.22
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- CORT 46.46
- PRCT 39.92
- Support Level
- CORT $49.51
- PRCT $79.30
- Resistance Level
- CORT $60.90
- PRCT $92.92
- Average True Range (ATR)
- CORT 2.69
- PRCT 3.60
- MACD
- CORT -0.85
- PRCT -1.20
- Stochastic Oscillator
- CORT 34.74
- PRCT 23.25
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.